

# International Agency for Research on Cancer



Governing Council  
Sixtieth Session

GC/60/19  
19/04/2018

*Lyon, 16–18 May 2018*  
*Auditorium*

## APPOINTMENT OF NEW MEMBERS OF THE SCIENTIFIC COUNCIL

1. In accordance with Article VI of the Statute and Resolution [GC/56/R17](#), the term of office of five members of the Scientific Council, namely Drs Stephen J. Chanock (USA), Ellen Kampman (The Netherlands), Ole Raaschou-Nielsen (Denmark), Martin Rösli (Switzerland) and Elisabete Weiderpass-Vainio (Finland) will be completed with the 2018 meeting of the Governing Council.
2. For the information of the Council, this leaves the following 20 members (10 women and 10 men) still serving on the Scientific Council: Drs Boris Alekseev (Russian Federation), Jonas Bergh (Sweden), Jenny Chang-Claude (Germany), Jerome Coffey (Ireland), Eugenia Dogliotti (Italy), Karima El Rhazi (Morocco), Kadir Mutlu Hayran (Turkey), Lalit Kumar (India), Dukhyoung Lee (Republic of Korea) and Giske Ursin (Norway) until 2019; Drs Adèle Green (Australia), Atsushi Ochiai (Japan), Roberto Salgado (Belgium), Pilar Sánchez Gómez (Spain) and Simon Tavaré (UK) until 2020; and Drs Salha Bujassoum Al Bader (Qatar), Jacqueline Clavel (France), Christine Friedenreich (Canada), Maria Sibilia (Austria) and João Viola (Brazil) until 2021.
3. The areas of expertise of those members remaining on the Scientific Council is provided below for consideration by the Governing Council in making its selection of new Scientific Council members from among the nominations.

Name	Country	Term of office	Gender	Field of expertise
Boris Ya. Alekseev	Russian Federation	2016 – 2019	M	Clinical oncology; cancer biomarkers; urology
Jonas Bergh	Sweden	2016 – 2019	M	Clinical oncology; cancer biomarkers; breast cancer
Jerome Coffey	Ireland	2016 – 2019	M	The management of breast and urological cancers, especially testicular germ cell tumours and prostate
Jenny Chang-Claude	Germany	2016 – 2019	F	Genetic epidemiology; breast, ovarian and colorectal cancers
Eugenia Dogliotti	Italy	2016 – 2019	F	Mechanisms of DNA repair and mutagenesis; molecular cancer epidemiology

Name	Country	Term of office	Gender	Field of expertise
Karima El Rhazi	Morocco	2016 – 2019	F	Cancer epidemiology and public health; cancer control; tobacco and respiratory epidemiology; nutritional epidemiology; quality of life
Kadir Mutlu Hayran	Turkey	2016 – 2019	M	Cancer epidemiology; cancer prevention; cancer clinical trials
Lalit Kumar	India	2016 – 2019	M	Clinical oncology; bone marrow/stem cell transplantation; multiple myeloma; gynecological malignancies
Dukhyoung Lee	RoK	2016 – 2019	M	Cancer prevention and control; cancer surveillance
Giske Ursin	Norway	2016 – 2019	F	Cancer registration; cancer epidemiology; nutritional epidemiology; gene-environment interactions
Adèle Green	Australia	2017 – 2020	F	Cancer etiology, prevention and implementation research, health services and policy
Atsushi Ochiai	Japan	2017 – 2020	M	Mechanisms of cancer progression, tumour microenvironment, cancer therapeutics
Roberto Salgado	Belgium	2017 – 2020	M	Molecular pathology, solid tumours, in particular breast cancer, circulating tumour biomarkers, next generation sequencing technologies, validation of biomarkers, innovative clinical trials incorporating genomics, quality assurance of genomic technologies
Pilar Sánchez Gómez	Spain	2017 – 2020	F	Brain tumours, preclinical tests, cancer therapeutics, molecular pathology, tumour microenvironment
Simon Tavaré	UK	2017 – 2020	M	Cancer genomics, evolutionary approaches to cancer, statistical bioinformatics for arrays and sequencing, computational biology, population genetics
Salha M. Bujassoum Al Bader	Qatar	2018 – 2021	F	Oncology; breast cancer; cancer screening
Jacqueline Clavel	France	2018 – 2021	F	Environmental epidemiology; childhood cancer; cancer registries
Christine Friedenreich	Canada	2018 – 2021	F	Cancer etiology, prevention and survival; physical activity
Maria Sibilia	Austria	2018 – 2021	F	Molecular medicine; tumour immunology; inflammation
João P.B. Viola	Brazil	2018 – 2021	M	Tumour immunology; cancer cell transformation
			TOTAL F = 10 M = 10	

4. In accordance with Article VI.2 of the Agency's Statute, the Governing Council is requested to select new members to be appointed to the Scientific Council from the attached list of experts, one each from Denmark, Finland, the Netherlands, Switzerland and the USA.

<p><b>DENMARK</b></p> <p>Dr Per Guldberg Danish Cancer Society Research Center, Copenhagen</p> <p><i>Field: Cancer biology; mechanisms of carcinogenesis</i></p> <p>Dr Anne Tjønneland Danish Cancer Society Research Center, Copenhagen</p> <p><i>Field: Nutritional and cancer epidemiology</i></p>	<p><b>FINLAND</b></p> <p>Dr Janne Mikael Pitkaniemi Finnish Cancer Registry, Helsinki</p> <p><i>Field: Biostatistics; epidemiology; statistical methods in genetic epidemiology; cancer registration</i></p>
<p><b>THE NETHERLANDS</b></p> <p>Dr Hendrike Cornelie (Hendriek) Boshuizen Department Statistics, Informatics and Mathematical Modelling, National Institute for Public Health and the Environment (RIVM), Bilthoven</p> <p><i>Field: Public health indicators (Health expectancy, DALYs), mathematical models for chronic diseases, nutritional cancer epidemiology, socio-economic and geographic differentials in health, cost-efficacy of preventive interventions, methods for dealing with measurement error (including regression calibration), for handling missing data, meta-analysis and statistical methods for handling -omics data.</i></p> <p>Dr Martje (Matty) Petronella Weijenberg Epidemiology Department, Maastricht University</p> <p><i>Field: Molecular epidemiology, colorectal cancer epidemiology, gene-environment interaction, nutrition, lifestyle, (epi)genetics, metabolic factors, cancer survivors, primary prevention, tertiary prevention.</i></p>	<p><b>SWITZERLAND</b></p> <p>Dr Sabine Rohrmann Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich</p> <p><i>Field: Diet/lifestyle and cancer risk; energy metabolism and components of the metabolic syndrome and their associations with cancer risk; factors influencing progression and survival of cancer patients</i></p>

<p><b>USA</b></p> <p>Dr James Robert Cerhan Mayo Clinic, Rochester, MN</p> <p><i>Field: Environmental, lifestyle, genetic and biologic factors in the etiology of lymphomas as well as myeloid, breast, endometrial, colorectal and prostate cancers; lifestyle, genetic, tumour/microenvironment and treatment factors in lymphoma patients that predict outcomes and quality of life</i></p> <p>Dr Susan M. Gapstur Epidemiology Research Program, American Cancer Society, Inc., Atlanta, GA</p> <p><i>Field: Lifestyle and environmental risk factors; cancer prevention and control</i></p>	
--	--

NB: The *curricula vitae* will be distributed to Governing Council members only.